Jan 7, 2021 4:01 pm EST Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jan 5, 2021 7:00 am EST Cerecor Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS
Dec 22, 2020 1:00 pm EST Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease
Dec 16, 2020 7:00 am EST Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
Dec 8, 2020 7:00 am EST Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma
Dec 1, 2020 7:00 am EST Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II
Nov 17, 2020 7:00 am EST Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG
Nov 9, 2020 4:01 pm EST Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update
